about
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer PatientsTreatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature reviewDermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.Microsatellite instability in melanoma: a comprehensive review.Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma.Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.[The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer
P50
Q26784564-CEDC0EBB-DA9A-4009-AE4E-71217630C495Q26999394-5AF90999-CD28-42AF-8F40-88701F367191Q36113525-CDCCC4B8-E024-4F2E-81C8-D670703609F1Q38668780-519CA4BE-C884-4744-8ADA-8D61E5A4D7A5Q38806400-D9C6BB4A-42E1-44A4-B1F8-401B38F3F1E1Q39636250-0868CA99-431C-428D-8380-1AB949059C74Q50901184-FF94E4AB-CA78-4DAF-B6E1-724A5311E38DQ53121550-5C783C73-D40C-46EE-901B-57BED522CC2BQ91289121-C4FD11F8-EC42-48BB-AA51-81CC7BFBDB23
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ondřej Kubeček
@en
Ondřej Kubeček
@nl
type
label
Ondřej Kubeček
@en
Ondřej Kubeček
@nl
prefLabel
Ondřej Kubeček
@en
Ondřej Kubeček
@nl
P108
P31
P496
0000-0003-2105-625X